Literature DB >> 11130391

Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?

A Wolk, S O Andersson, C S Mantzoros, D Trichopoulos, H O Adami.   

Abstract

Further well designed studies are urgently needed to clarify if use of prostate-specific antigen (PSA) as a diagnostic test for prostate cancer can be improved by incorporating measurements of serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding-protein 3 (IGFBP-3), and if these measurements might also identify men at higher risk.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11130391     DOI： 10.1016/S0140-6736(00)03266-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  5 in total

1.  The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5.

Authors:  W Zesławski; H G Beisel; M Kamionka; W Kalus; R A Engh; R Huber; K Lang; T A Holak
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

2.  Prostate cancer: serum and tissue markers.

Authors:  G J Miller; M K Brawer; W A Sakr; J B Thrasher; R Townsend
Journal:  Rev Urol       Date:  2001

Review 3.  IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth?

Authors:  W Zumkeller
Journal:  Mol Pathol       Date:  2001-10

4.  Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg rat.

Authors:  Zhuohua Wang; Raul M Luque; Rhonda D Kineman; Vera H Ray; Konstantin T Christov; Daniel D Lantvit; Tomoyuki Shirai; Samad Hedayat; Terry G Unterman; Maarten C Bosland; Gail S Prins; Steven M Swanson
Journal:  Endocrinology       Date:  2007-12-13       Impact factor: 4.736

5.  Stromally expressed c-Jun regulates proliferation of prostate epithelial cells.

Authors:  Wenhua Li; Chin-Lee Wu; Phillip G Febbo; Aria F Olumi
Journal:  Am J Pathol       Date:  2007-08-16       Impact factor: 4.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.